Resumen
Objetivo: Analizar la complejidad de la obesidad y clasificar sus subtipos en función de criterios diagnósticos, además de enfatizar la importancia de la actividad física y la preservación de la aptitud cardiorrespiratoria y los abordajes específicos y multidisciplinarios necesarios para combatir estas complejas condiciones. Revisión bibliográfica: Esta revisión abordó cuatro tipos de obesidad, cada uno con características clínicas y metabólicas distintas. Los Individuos Obesos Metabólicamente Saludables muestran obesidad, pero aparentemente carecen de trastornos metabólicos asociados. En contraste, los Individuos Obesos Metabólicamente Anormales incluyen a aquellos con sobrepeso y síndrome metabólico, caracterizándose por alteraciones en biomarcadores y un perfil metabólico adverso. La Obesidad Metabólica en Individuos con Peso Corporal Normal desafía las expectativas, revelando trastornos metabólicos en personas aparentemente dentro de los límites normales de peso. Y la Obesidad Sarcopénica presenta una intersección desafiante entre la obesidad y la pérdida relacionada con la edad de la masa muscular, requiriendo enfoques para preservar la función física. Consideraciones finales: Las estrategias personalizadas son esenciales para abordar la diversidad de fenotipos de obesidad. Comprender los diferentes subtipos es crucial para desarrollar estrategias de prevención y tratamiento más efectivas, con el objetivo de reducir el peso, promover la salud metabólica y la calidad de vida.
Referencias
BATSIS JA, VILLAREAL DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol, 2018; 14(9): 513-537.
BLÜHER M. Metabolically Healthy Obesity. Endocr Rev, 2020; 41(3): bnaa004.
BRADSHAW PT, et al. Incidence of components of metabolic syndrome in the metabolically healthy obese over 9 years follow-up: the Atherosclerosis Risk In Communities study. Int J Obes (Lond), 2018; 42(3): 295-301.
CHEN Q, et al. Metabolically Abnormal But Normal-Weight Individuals Had a Higher Risk of Type 2 Diabetes Mellitus in a Cohort Study of a Chinese Population. Front Endocrinol (Lausanne), 2021; 12: 724873.
COLLELUORI G e VILLAREAL DT. Aging, obesity, sarcopenia and the effect of diet and exercise intervention. Exp Gerontol, 2021; 155: 111561.
DE LORENZO A, et al. New obesity classification criteria as a tool for bariatric surgery indication. World J Gastroenterol, 2016; 22(2): 681-703.
DE TORO-MARTÍN J, et al. Precision Nutrition: A Review of Personalized Nutritional Approaches for the Prevention and Management of Metabolic Syndrome. Nutrients, 2017; 9(8): 913.
DUQUE AP, et al. Emerging concepts in metabolically healthy obesity. Am J Cardiovasc Dis, 2020; 10(2): 48-61.
EL BIZRI I e BATSIS JA. Linking epidemiology and molecular mechanisms in sarcopenic obesity in populations. Proc Nutr Soc, 2020; 14.
ELLULU MS, et al. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci, 2017; 13(4): 851-863.
HRUBY A e HU FB. The Epidemiology of Obesity: A Big Picture. Pharmacoeconomics, 2015; 33(7): 673-689.
HUNTER GR, et al. Sarcopenia and Its Implications for Metabolic Health. J Obes, 2019; 2019: 8031705.
KIRWAN JP, et al. The essential role of exercise in the management of type 2 diabetes. Cleve Clin J Med, 2017; 84(71): S15-S21.
KOLIAKI C, et al. Defining the Optimal Dietary Approach for Safe, Effective and Sustainable Weight Loss in Overweight and Obese Adults. Healthcare (Basel), 2018; 6(3): 73.
KURIYAN R. Body composition techniques. Indian J Med Res, 2018; 148(5): 648-658.
LAVIE CJ, et al. Healthy Weight and Obesity Prevention: JACC Health Promotion Series. J Am Coll Cardiol, 2018; 72(13): 1506-1531.
LIN H, et al. The prevalence, metabolic risk and effects of lifestyle intervention for metabolically healthy obesity: a systematic review and meta-analysis: A PRISMA-compliant article. Medicine (Baltimore), 2017; 96(47): e8838.
LIN X, LI H. Obesity: Epidemiology, Pathophysiology, and Therapeutics. Front Endocrinol (Lausanne), 2021; 12: 706978.
MAGKOS F. Metabolically healthy obesity: what's in a name? Am J Clin Nutr., 2019; 110(3): 533-539.
MAYORAL LP, et al. Obesity subtypes, related biomarkers & heterogeneity. Indian J Med Res., 2020; 151(1): 11-21.
NUTTALL FQ. Body Mass Index: Obesity, BMI, and Health: A Critical Review. Nutr Today, 2015; 50(3): 117-128.
PLUTA W, et al. Metabolic Obesity in People with Normal Body Weight (MONW)-Review of Diagnostic Criteria. Int J Environ Res Public Health, 2022; 19(2): 624.
RUDERMAN NB, et al. The "metabolically-obese," normal-weight individual. Am J Clin Nutr., 1981; 34(8): 1617-21.
SHUSTER A, et al. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol., 2012; 85(1009): 1-10.
ST-ONGE MP, GALLAGHER D. Body composition changes with aging: the cause or the result of alterations in metabolic rate and macronutrient oxidation?. Nutrition., 2010; 26(2): 152-155.
TAK YJ, LEE SY. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. Curr Obes Rep., 2021; 10(1): 14-30.
WHARTON S, et al. Obesity in adults: a clinical practice guideline. CMAJ, 2020; 192(31): E875-E891.
WILLIAMS R, PERIASAMY M. Genetic and Environmental Factors Contributing to Visceral Adiposity in Asian Populations. Endocrinol Metab (Seoul), 2020; 35(4): 681-695.
WU Q, et al. Metabolically healthy obesity: Is it really healthy for type 2 diabetes mellitus?. World J Diabetes, 2022; 13(2): 70-84.
YOO EG. Waist-to-height ratio as a screening tool for obesity and cardiometabolic risk. Korean J Pediatr., 2016; 59(11): 425-431.
ZAMBONI M, et al. Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis., 2008; 18(5): 388-95.
